CERUS partnered with POREX to supply components for the inactivation of pathogens in platelets and plasma.
CERUS INTERCEPT™ Blood System for Platelets and Plasma
The INTERCEPT™ Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT™ treatment is designed to inactivate established transfusion threats including Hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, Malaria and Dengue.
Patients around the world rely on INTERCEPT™ Blood System. POREX consistently delivers the quantities with the quality and time-frame required.